Serum concentration of the IgG1 mAbs 4L6 and 5L7, and emerging anti-mAb responses following recombinant AAV administration.

<p>Levels of produced antibodies were measured in sera from immunized animals over time by a gp140 capture ELISA. SIV challenge is indicated by arrows. (<b>A</b>) Animals that received rAAV-5L7 IgG1. 84–05, 153–10 and 157–10 were given one ssAAV vector expressing both heavy and light chain of the antibody 5L7 IgG1. 111–09, 120–09 and 154–10 were given an equal mixture of two scAAV vectors expressing either heavy chain or light chain of the antibody 5L7 IgG1. (<b>B</b>) Animals that received rAAV-4L6 IgG1. All six animals were given one ssAAV vector expressing both heavy and light chain of the antibody 4L6 IgG1. (<b>C</b> and <b>D</b>) Antibody responses to 5L7 IgG1 and 4L6 IgG1, respectively, following recombinant AAV administration. Humoral immune responses were measured in sera from immunized animals over time by ELISA. The reactivity of serum was tested against homologous purified protein using a conjugated anti-lambda secondary antibody for detection since both 5L7 IgG1 and 4L6 IgG1 bear a kappa light chain. (<b>E</b>) Reactivity of sera from 5L7 IgG1 recipients to purified mAbs and immunoadhesins at week 10 after AAV administration. (<b>F</b>) Reactivity of sera from 4L6 IgG1 animals to purified mAbs and immunoadhesins at week 6 after AAV administration.